在L-DOPA诱导的运动障碍症中,持续的COX-2上调没有受到celecoxib抑制的影响
Maurício Dos Santos Pereira1, Elaine Del Bel2
1The Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Department of Basic and Oral Biology, FORP, Campus USP, University of São Paulo, Av. Café, s/no, Ribeirão Preto 14040-904, Brazil.
Neuropharmacology
|June 14, 2025
概括
在帕金森病模型中,循环氧化酶-2 (COX-2) 表达与L-DOPA诱导的动力障碍 (LID) 严重程度相关. 抑制COX-2降低了炎症标志物,但没有缓解LID症状,这表明涉及非PGE2通路.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 生物化学 生物化学
背景情况:
- 神经炎症显著导致L-DOPA诱导的动力障碍 (LID),这是帕金森病 (PD) 治疗的一个常见并发症.
- 循环氧化酶-2 (COX-2) 在功能障碍模型中是上调调的,但其在LID病原发生中的确切作用尚不清楚.
研究的目的:
- 在半帕金森症小鼠中调查COX-2表达模式与异常非自愿运动 (AIMs) 以及FosB/ΔFosB表达的关系.
- 评估COX-2抑制剂在治疗或预防LID方面的疗效.
主要方法:
- 半帕金森症小鼠接受L-DOPA,AIM得分和分子分析在不同的时间点进行.
- 已确定的LID被治疗为Celecoxib或Indomethacin;另一组在LID发展期间接受了Celecoxib.
- 测量了COX-2表达,AIMs,FosB/ΔFosB和前列腺素E2 (PGE2) 的水平.
主要成果:
- 14天后,COX-2表达与LID发展相关,以及AIM的严重程度和FosB/ΔFosB水平.
- 抑制COX-2并没有改变AIM或COX-2/FosB/ΔFosB的表达,但显著降低了PGE2水平.
- COX-2 局部化在没有多巴胺基纤维的条状区域,与神经元标记物共局部化.
结论:
- 通过独立于PGE2介导的神经炎症的机制,COX-2上调可能会导致LID持久性.
- 需要进一步的研究来阐明COX-2在LID中的确切作用,并探索替代治疗点.
相关概念视频
01:24Parkinson's Disease: Treatment
239
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
239
01:28Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
281
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
281
01:23Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
228
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
228
01:21Drugs for Treatment of Constipation-Predominant IBS
146
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
146
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
501
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
501
01:29Drugs Affecting Neurotransmitter Synthesis
1.3K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.3K